Search research articles
Contact Us
Filters
Showing results (141-150 of 227) with videos related to
Page
of 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B Atkins, F Stephen Hodi, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2016
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Amy K Erbe, Wei Wang, Jacob Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
David F McDermott, Jeffrey A Sosman, Rene Gonzalez, et al.
European Urology
|
July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
Brian I Rini, Robert J Motzer, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J Motzer, Brian I Rini, David F McDermott, et al.
JAMA Oncology
|
December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Robert J Motzer, Thomas Powles, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2024
Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes
Wenxin Xu, Valerie Gaborieau, Samuel M Niman, et al.
Cancer Immunology Research
|
February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J Martini, Lana Hamieh, Rana R McKay, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study
Uday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
European Urology
|
April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
Page
of 23
Search research articles
Search
Showing results (141-150 of 227) with videos related to
Sort By:
Page
of 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Michael B Atkins, F Stephen Hodi, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2016
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Amy K Erbe, Wei Wang, Jacob Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
David F McDermott, Jeffrey A Sosman, Rene Gonzalez, et al.
European Urology
|
July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
Brian I Rini, Robert J Motzer, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J Motzer, Brian I Rini, David F McDermott, et al.
JAMA Oncology
|
December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Robert J Motzer, Thomas Powles, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 3, 2024
Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes
Wenxin Xu, Valerie Gaborieau, Samuel M Niman, et al.
Cancer Immunology Research
|
February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J Martini, Lana Hamieh, Rana R McKay, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study
Uday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.
European Urology
|
April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
Page
of 23